Physician profile
Mitchell W Pfeiffer
NPI 1447410964
$7,076.57
in general payments reported to CMS, 2019-2025
50 companies · $78.64 in 2025
The $78.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,380 · 2020: $1,150 · 2021: $1,068 · 2022: $1,333 · 2023: $1,719 · 2024: $348 · 2025: $78.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,146.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,167.03 | 2019-2025 | |
| Novo Nordisk INC | $939.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $682.84 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $399.25 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.72 | 2019-2023 | Synjardy, Jardiance, Spiriva Respimat |
| Pfizer INC. | $336.83 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $317.13 | 2019-2024 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $268.90 | 2019-2023 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $195.85 | 2019-2023 | Verquvo, Pneumovax 23, Vaxneuvance |
| Allergan, INC. | $185.62 | 2019-2020 | |
| Astellas Pharma US INC | $162.44 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $160.11 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $128.15 | 2019-2023 | Austedo Xr, Ajovy |
| Currax Pharmaceuticals LLC | $121.48 | 2021-2024 | Contrave, Onzetra Xsail |
| Amgen INC. | $119.53 | 2019-2023 | Repatha, Otezla |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Pfeiffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.